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the MLP to the trial data showed that timolol-treated patients
had a higher risk of developing night IOP peaks than travoprost-
treated patients. The estimates were 57.8% versus 58.2% (P <
0.90) respectively for travoprost and latanoprost using 8:00
IOPs, but 43.6% versus 50.0% (P < 0.05) with 10:00 IOPs, and
43.9% versus 53.3% (P < 0.005) using 16:00 IOPs. CONCLU-
SION: IOP measures during the day are correlated with night
measures. The MLP results suggest that control of IOP in late
afternoon might also prevent night IOP peaks. Prostaglandin
analogues were associated with a lower probability of late after-
noon and night time IOP peaks than timolol. The travoprost
night IOP peak probability was lower than that for latanoprost.
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OBJECTIVE: To conﬁrm randomized clinical trial results
showing that travoprost reduces IOP with sustained efﬁcacy 
in the afternoon, 20–24 hours after the last instillation.
METHODS: Patients treated with a prostaglandin analogue
monotherapy for ocular hypertension or glaucoma was included
in this cross-sectional retrospective survey. Demographics, anam-
nesis, previous treatments were collected from medical chart.
IOP and the last instillation time were collected during the visit.
ANOVA, logistic regressions and propensity scores were used to
compare the 2 treatments. RESULTS: 2503 patients were
included by 494 ophthalmologists. Patients averaged 64 years
old (45% male). 2052 patients were treated with travoprost or
latanoprost and the last instillation time was documented for
1702 of them. 1241 patients had properly used their medication
within the previous day and 461 patients had failed to take it.
IOP was 25mmHg at diagnosis and 22.5mmHg at the initiation
of the current treatment. The two groups were comparable but
travoprost-treated patients had a shorter disease and treatment
duration. When the instillation was given during the day before,
travoprost better controlled IOP at 12.00 and 16.00 hours
(16.79 versus 17.51mmHg; P < 0.05) and after 16.00 (16.55
versus 17.67mmHg; P < 0.003). When the interval time between
the instillation and IOP recordings was >24 hours, travoprost-
treated patients had a lower IOP (16.76 versus 17.80mmHg; P
< 0.002). The percentage of patients reaching the pre-deﬁned
target IOP was higher with travoprost than with latanoprost,
independent of instillation time (81.9% versus 67.3% (P <
0.0001) when intake was the previous day, and 78.5% versus
68.3% (P < 0.03) when intake >24 hours. These differences per-
sisted after adjustment for confounding factors. CONCLUSION:
This observational survey conﬁrmed the previous clinical data
demonstrating that travoprost uniformly controls IOP through
the day with a strong remnant effect, since IOP remains well con-
trolled for more than 24 hours.
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OBJECTIVES: The purpose of this study was to assess the incre-
mental effect on intraocular pressure (IOP) reduction when
changing from latanoprost-timolol ﬁxed combination in the
treatment of primary open-angle glaucoma (POAG).
METHODS: Retrospective analysis was conducted of the
Glasgow Royal Inﬁrmary Glaucoma database. The database was
comprised of computerized medical records of all POAG patients
treated at the Glasgow Royal Inﬁrmary from 1981 to present.
Data elements recorded for each patient included demographics,
diagnosis, and treatment history. Treatment history included
initial and subsequent medication regimens. Patient IOP was
measured before and after treatment change and mean change
with 95% C.I. was calculated. RESULTS: Eighty-three cases of
POAG were identiﬁed where treatment was changed from
evening dosed latanoprost to latanoprost-timolol once daily to
achieve or maintain lower target IOP. The mean incremental
reduction in IOP was 2.01mmHg (95% C.I. 1.22–2.81). 
CONCLUSIONS: In POAG patients treated with latanoprost
who require lower target pressures to control their disease,
latanoprost-timolol ﬁxed combination provides additional incre-
mental IOP reduction. Additional research should be conducted
to further characterize and understand the importance of efﬁcacy
of combination therapy in the treatment of glaucoma.
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OBJECTIVE: To compare the efﬁcacy of latanoprost, bimato-
prost and travoprost for controlling IOP using data published 
in the literature. METHODS: Randomized clinical trials were
identiﬁed on Medline and Embase using the following key
words: glaucoma, ocular hypertension, randomization, trial,
latanoprost, bimatoprost and travoprost. The trials had to
compare at least two prostaglandins head-to-head in monother-
apy. Cross-over experimental designs were excluded. Sample
size, IOP at inclusion and ﬁnal visit, age, gender, race and period
of follow-up were collected. Daily average IOP was estimated
when measurements were available over the study period.
Latanoprost was used as the reference treatment for compar-
isons. Multiple regression analyses estimated the effects of the
different treatments on IOP after controlling for IOP at inclu-
sion and duration of follow-up. All analyses were weighted using
number of patients (inversely proportional to variance weights).
RESULTS: A total of 224 papers were identiﬁed, including 15
randomized clinical trials, which compared two prostaglandin
monotherapies. Six studies were excluded: three cross-over
designs, one with daily intake not in accordance with the SmPC,
one combination study, and one without documented average
IOP. The average age varied from 56.7 to 68.8 years and the IOP
at inclusion from 22.3 to 26.5mmHg. 378 patients were treated
with bimatoprost, 385 with travoprost and 548 with
latanoprost. After adjusting for baseline IOP and period of
follow-up, both patients treated with travoprost and bimato-
prost tended to have a lower IOP (-0.63mmHg [-1.56; 0.30]
and -0.78 mmHg [-1.75; 0.18], respectively) than those treated
with latanoprost. After adjusting for IOP at baseline, follow-up
period, age and gender the treatment effects were -0.72 [-2.02;
0.57] and -0.69 [-2.04; 0.65] for travoprost and bimatoprost,
respectively. CONCLUSION: Based on the information available
in the literature, travoprost and bimatoprost may have greater
